Background:

BW 246C is a DP receptor agonist.

The prostaglandin D2 (PGD2) receptors, members of G protein-coupled receptors, bind and are activated by prostaglandin D2. PGD2 receptors include the following proteins prostaglandin D2 receptor 1 (DP1) and prostaglandin D2 receptor 2 (DP2).

In vitro: BW 246C was found to be the less active C-8 diastereomer of the DP receptor agonist its analog BW 245C, having 70-fold less activity than that of BW 245C. For BW 245C, a significant species variation was observed in the anti-aggregatory potency so that it was about one hundred times more effective than in the human in the rat. However, the relative potencies of PGI2 and PGE1 were found to be similar in both species. Moreove, it was observed that in radioligand binding studies BW 245C had a high affinity and selectivity for PGD2 platelet receptors, and the binding to PGI2 or PGE2 receptors was not found [1].

In vivo: Animal study showed that, an intravenous bolus injection of 250 μg/kg BW 245C to spontaneously hypertensive rats was able to lower both systolic (-23%) and diastolic (-34%) blood pressure [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Town, M. H.,Casals-Stenzel, J. and Schillinger, E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins 25, 13-28 (1983).